Table 3.
Synergistic antitumor activity of combining sunitinib (S), dasatinib (D) with everolimus (E) in ovarian cancer cells.
| Cell | Combination | Fold Reduction (IC50) | Fold Reduction (IC75) | CI | |||||
|---|---|---|---|---|---|---|---|---|---|
| S | D | E | S | D | E | ED50 | ED75 | ||
| MDAH 2774 |
SE (2:1) | 6.33 | NA | 200.1 | 1.04 | NA | 529271 | 0.32 | 0.097 |
| DE (1:5) | NA | 28.7 | 825.9 | NA | 13.01 | 131663 | 0.035 | 0.077 | |
| SD (10:1) | 4.21 | 9.56 | NA | 2.2 | 110.42 | NA | 0.37 | 0.46 | |
| SDE (10:1:5) | 12.8 | 28.7 | 814.8 | 3.2 | 161.12 | 1631020 | 0.11 | 0.32 | |
| SKOV3 | SE (10:1) | 3.51 | NA | 29.2 | 1.58 | NA | 2811 | 0.32 | 0.63 |
| DE (1:1) | NA | 6.2 | 72.3 | NA | 3.51 | 1201 | 0.18 | 0.29 | |
| SD (10:1) | 3.26 | 2.3 | NA | 2.95 | 15.37 | NA | 0.74 | 0.4 | |
| SDE (10:1:1) | 6.72 | 4.76 | 55.9 | 4.78 | 25.15 | 8591 | 0.38 | 0.25 | |
| A2780CR | SDE (40:1:2) | 26.93 | 15.06 | 3.39 | 5.78 | 4.59 | 18.05 | 0.37 | 0.44 |
| OVCAR8 | SDE (1000:10:1) | 5.64 | 4.95 | 6.93 | 2.55 | 2.53 | 26.98 | 0.51 | 0.82 |
IC50 and IC75: concentrations giving 50% and 75% inhibition; ED50 and 75: effective doses giving 50% and 75% inhibition; CI: combination index. S: sunitinib; D: dasatinib; E: everolimus.